SCL Science Inc. (KOSDAQ:246960)

Market Cap	68.68B
Revenue (ttm)	4.74B
Net Income (ttm)	-3.73B
Shares Out	8.48M
EPS (ttm)	-513.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,894
Average Volume	3,798
Open	8,050.00
Previous Close	8,120.00
Day's Range	8,020.00 - 8,190.00
52-Week Range	7,530.00 - 11,850.00
Beta	0.45
RSI	48.52
Earnings Date	May 13, 2025

About SCL Science

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products includes BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal which is used for the specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; and I...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 246960

Financial Performance

In 2024, SCL Science's revenue was 4.74 billion, an increase of 258.30% compared to the previous year's 1.32 billion. Losses were -3.73 billion, -25.79% less than in 2023.